The Choroideremia market report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Choroideremia: An Overview
Choroideremia is a condition categorized by progressive vision loss which usually affects males. The first and foremost symptom of this condition is an impairment of night vision, also known as night blindness, which can occur in early childhood, as well as, tunnel vision (a narrowing field of vision), and visual activity (decrease in the ability to see details). Other names for this condition are: Collapse Section, choroidal sclerosis progressive tape choroidal dystrophy, and TCD
Choroideremia is inherited in an X-linked recessive pattern. The CHM gene is located on the X chromosome, which is one of the two sex chromosomes. In males (who have only one X chromosome), one altered copy of the gene in each cell is sufficient to cause the condition.
Choroideremia Market Key Facts
According to the National Organization for Rare Diseases (NORD), choroideremia affects primarily males. However, a small number of females develop the disorder as a result of a genetic process that inactivates the normal gene and leaves only the dysfunctional gene active.
According to the article by Kapetanovic et al. (2019), it is estimated that 1 in 50,000 males are affected by Choroideremia.
According to the National Institute of Health (NIH), the prevalence of choroideremia is estimated to be 1 in 50,000–100,000 people. However, it is likely that this condition is underdiagnosed because of its similarities to other eye disorders.
As per the study by Galvin et al. (2020), the socioeconomic impact of inherited retinal dystrophies (IRDs) in the United Kingdom, out of total Inherited Retinal Diseases (IRD) the lowest proportion of cases was for choroideremia (1.4%) in the UK.
Choroideremia Market Size is expected to increase during the forecast period owing to the rising prevalence of Choroideremia, along with the expected launch of emerging therapies such as Spark Therapeutics’ SPK-7001, Biogen‘s BIIB111 (AAV2-REP1), and 4D Molecular Therapeutics’ 4D-110. The pipeline for Choroideremia brings a positive ray of hope for a better treatment pattern in the market in the upcoming years.
The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Choroideremia market size by analyzing the impact of current and emerging therapies in the market. It also provides a detailed assessment of the market drivers & barriers, unmet needs, and emerging technologies.
The report gives a thorough detail of the Choroideremia market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MoA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
The epidemiology section covers insights about the historical and current Choroideremia patient pool and forecasted trends for every seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Choroideremia Epidemiology Segmentation
Total Prevalence of Choroideremia
Gender-specific Prevalence of Choroideremia
Diagnosed and Treatable Cases of Choroideremia
Choroideremia Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Choroideremia market or expected to get launched in the market during the study period. The analysis covers Choroideremia market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The report also covers the Choroideremia Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.
Get the PDF Sample of the Report:- https://www.delveinsight.com/sample-request/choroideremia-market
Choroideremia Therapeutics Analysis
Some of the key companies in the Choroideremia Market include:
4D Molecular Therapeutics (4DMT)
And many others.
Choroideremia Therapies covered in the report include:
And many more.
The launch of these emerging therapies is expected to significantly impact the treatment scenario of Choroideremia in the coming years.
Get More Detailed Insights into the Emerging Therapies & Key Companies:- https://www.delveinsight.com/sample-request/choroideremia-market
Table of Content
1. Key Insights
2. Executive Summary
3. Choroideremia Competitive Intelligence Analysis
4. Choroideremia Market Overview at a Glance
5. Choroideremia Disease Background and Overview
6. Choroideremia Patient Journey
7. Choroideremia Epidemiology and Patient Population
8. Choroideremia Treatment Algorithm, Current Treatment, and Medical Practices
9. Choroideremia Unmet Needs
10. Key Endpoints of Choroideremia Treatment
11. Choroideremia Marketed Products
12. Choroideremia Emerging Therapies
13. Choroideremia Seven Major Market Analysis
14. Attribute Analysis
15. Choroideremia Market Outlook (7 major markets)
16. Choroideremia Access and Reimbursement Overview
17. KOL Views on the Choroideremia Market.
18. Choroideremia Market Drivers
19. Choroideremia Market Barriers
21. DelveInsight Capabilities
*The table of contents is not exhaustive; the final content may vary.
Request Sample Report here:- https://www.delveinsight.com/sample-request/choroideremia-market
Other Latest Reports By DelveInsight
DelveInsight’s, “Bevacizumab Biosimilar Insight” report provides comprehensive insights about 40+ companies and 40+ marketed and pipeline drugs in the Bevacizumab Biosimilars landscape. The report also covers the marketed and pipeline drug profiles, including clinical and non-clinical stage products.
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States